

# 만성 정신분열증환자에 대한 Sertraline 병합치료 효과

이민수\*<sup>†</sup> · 김용구\* · 이상규\* · 서광윤\*

## Adjuvant Sertraline Treatment for Chronic Schizophrenia : A Randomized, Double Blind, Placebo-Controlled Study

Min-Soo Lee, M.D.,\*<sup>†</sup> Yong-Ku Kim, M.D.,\*  
Sang-Kyu Lee, M.D.,\* Kwang-Yoon Suh, M.D.\*

### ABSTRACT

**Objective :** To evaluate the clinical efficacy of adjuvant sertraline treatment in chronic schizophrenic patients, we carried out a double-blind, placebo controlled study.

**Method :** Thirty six inpatients who fulfilled DSM-III-R criteria for chronic schizophrenia were randomly assigned to sertraline and placebo groups in a double-blinded fashion. A history of at least 2 years of illness and at least six months of hospitalization were prerequisites for inclusion in the study. Patients were received sertraline 50mg or placebo for 8 weeks in addition to their routine haloperidol regimen. Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI), Simpson-Angus Scale(S-A) were evaluated at 5 points ; baseline, 2, 4, 6, and 8 weeks of treatment.

**Results :** The groups were controlled for age, gender, and length of illness. There were no significant differences in three PANSS factors(positive, negative, general), CGI, and S-A scale scores at any between sertraline and placebo treatment.

**Conclusion :** This placebo controlled study showed no significant effects of sertraline on negative and positive symptoms in chronic schizophrenic patients.

**KEY WORDS :** Chronic schizophrenia · Double-blind · Sertraline · Haloperidol.

### 서 론

가  
clozapine, risperidone  
(antagonist) , ,  
가 (Kane  
1988 ; Borison 1992 ; Pickar 1992),  
(ne -  
uron) (raphe nucleus)  
(axoaxonal synapse)  
(agonist)  
(Bleich 1988).  
uvoxamine, sertraline (selective  
serotonin reuptake inhibitors ; SSRIs)  
가  
(Goff 1990, 1995 ; Goldman Janecek 1990 ;  
Silver Nassar 1992 ; Hwang 1993 ; Spina 1994 ;

Department of Neuropsychiatry, College of Medicine, Korea University, Seoul, Korea

<sup>†</sup> : , 136 - 705 126 - 1  
) (02) 920 - 5354, ) (02) 923 - 3507

Thakore 1996).  
 Goff (1990) (open study) 9  
 fluoxetine 6

, Silver Nassar(1992) fl-  
 uvoxamine  
 fluoxetine

(Spina 1994 ; Goff 1995). sertraline  
 Thakore (1996)  
 sertraline

sertraline

haloperidol fluoxetine  
 가

, haloperidol

haloperidol 가

(Goff 1991 ; Ames 1993),

(Arya 1994).

sertraline

paroxetine

SSRIs

sertraline

fluoxetine

P450 IID6

가 SSRIs 15 20%

(Doogan Caillard 1988). Desipramine

fluoxetine paroxetine desipramine

rate) 400%

sertraline

(Preskorn 1993).

sertraline

## 연구대상 및 방법

### 1. 연구대상

R

, 6

36

DSM - III -

2

### 3. 추체외로 부작용

Simpson - Angus

6

( , , , , , , , , , )  
 , B )

## 2. 연구방법

2

haloperidol 가 haloperidol  
 benzodiazopine benzotropine met -  
 hylate

A B

; 10 , ; 8 ) sertraline 1 50mg 8  
 , B ( 18 , ; 10 , ; 8

) sertraline 8  
 가 , 2 , 4 , 6 , 8

Positive and Negative Syndrome Scale( PANSS,  
 Kay 1987), Clinical Global Impression Scale( CGI, Na-  
 tional Institute of Mental Health 1970)

가 가 Simpson - Angus sc -  
 ale( S - A scale, Simpson Angus 1970)

가 3 가 4 가  
 가 PANSS

0.89(p<0.05), CGI 0.82(p<0.05), S - A scale

0.92(p<0.05)

SPSS/PC +

two - way repeated me -

asure ANOVA Student' s t - test

p 0.05

## 연구결과

### 1. 인구학적 및 임상적 특징

sertraline placebo ,  
 , haloperidol , , ( ,  
 ) (Table 1).

### 2. 치료 효과

Sertraline placebo PANSS , ,  
 (Table 2, 3, 4).

CGI

(Table 5).

**Table 1.** Demographic and clinical characteristic of subjects at baseline

Variable	Sertraline Group (N=18)	Placebo Group (N=18)	Significance*
Sex (male : female)	10 : 8	10 : 8	
Age (year)	40.1 ± 8.2	39.7 ± 9.9	n.s.
Duration of illness (year)	10.1 ± 6.5	10.8 ± 6.1	n.s.
Dose of haloperidol (mg/day)	19.2 ± 13.5	21.9 ± 15.4	n.s.
Weight	60.2 ± 6.5	61.3 ± 10.1	n.s.
Height	162.9 ± 6.2	160.8 ± 5.9	n.s.
Blood pressure			
Systole	104.4 ± 7.0	111.1 ± 11.8	n.s.
Diastole	67.7 ± 8.0	69.4 ± 8.7	n.s.
Pulse rate	89.6 ± 12.3	89.7 ± 12.1	n.s.
Subtype			
Paranoid	8	7	
Undifferentiated	10	9	
Disorganized		2	

\*Student t-test, two-tailed (mean ± S.D.)  
n.s : non-significant

**Table 2.** Comparison of PANSS positive scale score by group\*

Group	Baseline	Week 2	Week 4	Week 6	Week 8
Sertraline (n=18)	17.88(5.58)	17.72(5.62)	17.77(5.63)	17.66(5.33)	17.44(5.29)
Placebo (n=18)	19.38(4.90)	20.11(5.73)	20.88(6.37)	21.05(6.31)	20.77(6.57)

Each value represents the mean ± S.D  
\*A mixed model repeated measures ANOVA with group a between subjects factor and base/week  
2, 4, 6, 8 as a within subjects factors.  
Group effect : F=2.13, df=1/34, n.s  
Time effect : F=1.87, df=4/136m n.s  
Group x Time interaction : F=3.29, df=4/136, p<0.05

**Table 3.** Comparison of PANSS negative scale by group\*

Group	Baseline	Week 2	Week 4	Week 6	Week 8
Sertraline (n=18)	21.00(6.77)	21.44(7.57)	22.39(7.36)	21.44(6.77)	21.27(6.69)
Placebo (n=18)	20.91(5.60)	21.33(4.52)	21.16(4.82)	21.83(5.56)	21.11(5.38)

Each value represents the mean ± S.D  
\*A mixed model repeated measures ANOVA with group a between subjects factor and base/week  
2, 4, 6, 8 as a within subjects factors.  
Group effect : F=0.02, df=1/34, n.s  
Time effect : F=1.62, df=4/136m n.s  
Group x Time interaction : F=1.18, df=4/136, n.s

(Table 6).

고찰  
sertraline  
Thakore (1996)  
가

**Table 4.** Comparison of PANSS general psychopathology scale score by group\*

Group	Baseline	Week 2	Week 4	Week 6	Week 8
Sertraline (n=18)	38.88 (9.93)	39.05 (10.47)	39.77 (10.82)	38.94 (9.68)	38.22 (9.29)
Placebo (n=18)	39.44 (5.80)	40.61 (8.02)	41.27 (9.44)	39.83 (12.77)	38.33 (11.72)

Each value represents the mean ± S.D  
\*A mixed model repeated measures ANOVA with group a between subjects factor and base/week  
2, 4, 6, 8 as a within subjects factors.  
Group effect : F=0.09, df=1/34, n.s  
Time effect : F=1.93, df=4/136m n.s  
Group x Time interaction : F=3.44, df=4/136, n.s

**Table 5.** Comparison of clinical global improvement score by group\*

Group	Baseline	Week 2	Week 4	Week 6	Week 8
Sertraline (n=18)	3.88(1.49)	3.88(1.60)	3.88(1.53)	3.88(1.53)	3.72(1.40)
Placebo (n=18)	4.27(1.01)	4.27(1.01)	4.33(1.08)	5.16(3.86)	5.00(3.91)

Each value represents the mean ± S.D  
\*A mixed model repeated measures ANOVA with group a between subjects factor and base/week  
2, 4, 6, 8 as a within subjects factors.  
Group effect : F=1.76, df=1/34, n.s  
Time effect : F=0.74, df=4/136m n.s  
Group x Time interaction : F=1.04, df=4/136, n.s

**Table 6.** Comparison of simpson-angus score by group\*

Group	Baseline	Week 2	Week 4	Week 6	Week 8
Sertraline (n=18)	1.00(1.18)	1.11(1.27)	1.22(1.47)	1.39(1.68)	1.44(1.75)
Placebo (n=18)	1.72(1.84)	1.88(2.08)	2.16(2.25)	2.27(2.19)	2.33(2.22)

Each value represents the mean ± S.D  
\*A mixed model repeated measures ANOVA with group a between subjects factor and base/week  
2, 4, 6, 8 as a within subjects factors.  
Group effect : F=2.17, df=1/34, n.s  
Time effect : F=2.50, df=4/136m n.s  
Group x Time interaction : F=0.14, df=4/136, n.s

20

50mg sertraline  
12 BPRS  
35.7% 20.0%  
가 가  
가 8  
sertraline 가

Thakore (1996)

가 가

Thakore (1996)

, Thakore (1996) sertraline 12  
8 가

가 가 가 가

rtraline 50mg 8  
 가 haloperidol se - traline  
 가  
 fenfluramine  
 가 (>180  
 (Alphs  
 mg/day)  
 1989) 가  
 sertraline  
 가 가 36 sertraline  
 SSRIs 가 가 8  
 fluoxetine  
 fluvoxamine 1) PANSS  
 가 가 (Silver Nassar 1992, Goff CGI  
 1995), paroxetine 2) Simpson - Angus  
 가 ( 1996). 가  
 haloperidol sertraline  
 clozapine  
 , clozapine  
 (Breier 1994 ; Carpenter Jr  
 1995)  
 가  
 가  
 fluoxetine  
 , Baldessarini Marsh(1990)  
 fluoxetine  
 , Goff (1991) fluoxetine halop -  
 eridol 20% 가 , halo -  
 peridol 가  
 가 가 (Bleich  
 1988), fluoxetine 가 가  
 (down - regulation)  
 (Sommi 1987)  
 8 sertraline 가  
 ser -

## 결론

중심 단어 : Sertraline · Halop - eridol.

## 참고문헌

- 한창수 · 이민수 · 김표한(1996) : 만성 정신분열증 환자에서 파  
 록세틴과 할로페리돌 병합 투여시 증상의 변화. 생물정신  
 의학 3 (2) : 251-257  
**Alphs LD, Lafferman JA, Ross L, Bland W, Levine J (1989) :** *Fe-  
 nfluramine treatment of negative symptoms in older schizophrenic  
 inpatients. Psychopharmacol Bull 25 : 149-153*  
**Ames D, Wirshing WC, Marder SR, Yuwiler A, Brammer GL,  
 Midha KK, van Putten T (1993) :** *Adjunctive fluoxetine in ha-  
 loperidol stabilized schizophrenics. Presented at the First Intern-  
 ational Congress on Hormone, Brain and Neuropsychopharmacolo-  
 gy. Greece : 13-17*  
**Arya DK (1994) :** *Extrapyramidal symptoms with selective serotonin  
 reuptake inhibitors. Br J Psychiatry 165 : 728-733*  
**Baldessarini RJ, Marsh E (1990) :** *Fluoxetine and side effects. Arch  
 Gen Psychiatry 47 : 191-192*  
**Bleich A, Brown SL, Kahn R, van Praag HM (1988) :** *The role of  
 serotonin in schizophrenia. Schizophr Bull 14 (2) : 297-315*  
**Borison RL, Diamond BI, Pathiraja A, Meibach RC (1992) :** *Clini-  
 cal overview of risperidone, In : Novel antipsychotic drugs. Ed  
 by Meltzer, Raven press, New York pp233-239*  
**Breier A, Bushanan RW, Kirkpatrick B (1994) :** *Effects of clozap-  
 ine on positive and negative symptoms in outpatients with schizo-  
 phrenia. Am J Psychiatry 151 : 20-26*  
**Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga**

- CA(1995) : Patient response and resource management : Another view of clozapine treatment of schizophrenia. *Am J Psychiatry* 152 : 827-832
- Doogan DP, Caillard V(1988) : Sertraline ; A new anti-depressant. *J Clin Psychiatry* 49 (suppl) 46-51
- Goff DC, Brotman AW, Waites M, McCormick S(1990) : Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. *Am J Psychiatry* 147 (4) : 492-494
- Goff DC, Midha KK, Brotman AW, Waites M, Baldessarini RJ (1991) : Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. *Am J Psychiatry* 148 (6) : 790-792
- Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E(1995) : A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. *Psychopharmacol-Berl* 117 (4) : 417-423
- Goldman MB, Janecek HM(1990) : Adjunctive fluoxetine improves global function in chronic schizophrenia. *J Neuropsychiatry Clin Neurosci* 2 : 429-431
- Hwang MY, Martin AM, Lindenmayer JP(1993) : Treatment of schizophrenia with obsessive-compulsive features with serotonin reuptake inhibitor (letter). *Am J Psychiatry* 150 : 1127
- Kane J, Honigfeld G, Singer J, Meltzer H(1988) : Clozapine for the treatment-resistant schizophrenics : A double-blind comparison with chlorpromazine. *Arch Gen Psychiatry* 45 : 789-796
- Kay SR, Fiszbein A, Opler LA(1987) : The positive and negative syndrome scale (PANSS) for schizophrenia. *Biol Psychiatry* 20 : 219-222
- National Institute of Mental Health(1970) : Clinical Global Impressions. In : *Manual for the ECDEU Assessment Battery, 2nd rev ed*, Ed by Guy W, Bonato RR, Rockville, NIMH
- Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Raport MH(1992) : Clinical and biologic response to clozapine in patients with schizophrenia : Crossover comparison with fluphenazine. *Arch Gen Psychiatry* 49 : 345-353
- Preskorn SH(1993) : Pharmacokinetics of antidepressants : Why and how they are relevant to treatment. *J Clin Psychiatry* 54 (suppl 9) : 14-34
- Silver H, Nassar(1992) : Fluvoxamine improves negative symptoms in treated chronic schizophrenia : An add-on double-blind, placebo-controlled study. *Biol Psychiatry* 31 : 698-704
- Simpson GM, Angus JWS(1970) : A rating scale for extrapyramidal side effects. *Acta Psychiatr Scand* 212 (suppl) : 11
- Sommi RW, Crismon ML, Bowden CL(1987) : Fluoxetine : A serotonin-specific, second-generation antidepressant. *Pharmacotherapy* 7 : 1-15
- Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, Di-Risa AE, Caputi AP(1994) : Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. *Int Clin Psychopharmacol* 9 (4) : 281-285
- Thakore JH, Berti C, Dinan TG(1996) : Adjuvant sertraline treatment for chronic schizophrenia. p202 Abstracts of the XXth Collegium Internationale Neuro-Psychopharmacologicum Congress, Melbourne, Australia, June 23-27, 1996